Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927381 · ClinicalTrials.gov registry record
Retrospective Evaluation of CroFab - Efficacy in Severe Envenomation
A clinical trial, sponsored by BTG International.
- Completed
- Registry status
- 247
- Enrollment target
NCT00927381: Completed study, sponsored by BTG International.
NCT00927381 is a clinical trial that has completed, run by BTG International. The registered enrollment target is 247 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00927381 has completed, sponsored by BTG International.
- COMPLETED
- Registry status
- 247 participants
- Enrollment target
Study Summary
Retrospective observational review of severe envenomation treatment with CroFab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-01 |
What the finished NCT00927381 record still lists
NCT00927381 is an observational study that tracks outcomes without assigning an intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00927381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00927381 about?
NCT00927381 is a clinical study titled "Retrospective Evaluation of CroFab - Efficacy in Severe Envenomation". Retrospective observational review of severe envenomation treatment with CroFab
What is the current status of trial NCT00927381?
This trial is currently completed. The enrollment target is 247 participants. The study started on 2005-01. Estimated completion is 2005-01.
Who is sponsoring clinical trial NCT00927381?
This trial is sponsored by BTG International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia